HC Wainwright Has Lowered Expectations for Korro Bio (NASDAQ:KRRO) Stock Price

Key Points

• HC Wainwright has reduced the price target for Korro Bio (NASDAQ:KRRO) from $100.00 to $90.00, while maintaining a "buy" rating, indicating a potential upside of 462.85% from the current price.
• Other firms like Chardan Capital and Cantor Fitzgerald have given the stock "buy" and "strong-buy" ratings, respectively, with a consensus rating of "Buy" and an average price target of $101.00.
• Korro Bio recently reported an EPS of ($2.74), missing estimates, but exceeded revenue expectations with $1.46 million for the quarter.

Korro Bio (NASDAQ:KRRO - Free Report) had its price objective reduced by HC Wainwright from $100.00 to $90.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Korro Bio's Q3 2025 earnings at ($2.43) EPS, Q4 2025 earnings at ($2.26) EPS, FY2025 earnings at ($9.93) EPS, Q1 2026 earnings at ($2.23) EPS, Q2 2026 earnings at ($2.28) EPS, Q3 2026 earnings at ($2.34) EPS, Q4 2026 earnings at ($2.39) EPS and FY2026 earnings at ($9.23) EPS.

Several other analysts also recently commented on KRRO. Cantor Fitzgerald raised Korro Bio to a "strong-buy" rating in a research note on Tuesday, April 29th. Oppenheimer reduced their target price on Korro Bio from $155.00 to $90.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Finally, Chardan Capital reissued a "buy" rating and set a $25.00 price target on shares of Korro Bio in a research note on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $86.83.

Korro Bio Trading Down 2.7%

NASDAQ:KRRO traded down $0.54 during midday trading on Wednesday, reaching $19.72. The company had a trading volume of 162,738 shares, compared to its average volume of 115,044. The firm has a market capitalization of $185.17 million, a price-to-earnings ratio of -2.02 and a beta of 2.51. The stock's fifty day simple moving average is $14.32 and its 200-day simple moving average is $17.90. Korro Bio has a 12-month low of $10.29 and a 12-month high of $98.00.

Korro Bio (NASDAQ:KRRO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($2.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.54) by ($0.20). The business had revenue of $1.46 million during the quarter, compared to the consensus estimate of $0.41 million. As a group, sell-side analysts expect that Korro Bio will post -9.52 EPS for the current year.

Institutional Trading of Korro Bio

Large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN grew its stake in shares of Korro Bio by 32.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,392 shares of the company's stock valued at $129,000 after acquiring an additional 831 shares in the last quarter. Bank of Montreal Can acquired a new position in shares of Korro Bio during the fourth quarter valued at approximately $217,000. Legal & General Group Plc increased its stake in shares of Korro Bio by 664.1% during the fourth quarter. Legal & General Group Plc now owns 4,325 shares of the company's stock valued at $165,000 after acquiring an additional 3,759 shares during the period. Raymond James Financial Inc. acquired a new position in Korro Bio in the fourth quarter worth approximately $394,000. Finally, Barclays PLC acquired a new position in Korro Bio in the fourth quarter worth approximately $395,000. 13.18% of the stock is currently owned by institutional investors and hedge funds.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).